The upcoming webinar, hosted by Xtalks on September 29, 2026, shifts the focus from merely suppressing the placebo response to implementing a signal intelligence framework. By analyzing participant, rater, site, and study-level data, trial teams can better distinguish meaningful therapeutic effects from the background noise inherent in current measurement tools.
In section Releases
Tackling the Placebo Effect in Major Depressive Disorder Clinical Trials
High placebo response rates continue to undermine the detection of drug efficacy in Major Depressive Disorder trials, turning clinical data into a complex puzzle. Experts are set to examine how study design, patient selection, and rater practices contribute to measurement noise that obscures genuine clinical improvement.
Luka Lucić, PhD, and Svenja Wacker, PhD, from Cogstate will lead the session, detailing how trial teams can assess clinical coherence and apply targeted interventions. The discussion aims to equip professionals with strategies to identify risks to endpoint quality and strengthen the ability to measure authentic change in MDD patients.
Comments (0)
No comments yet. Be the first!